BACKGROUND: Little is known about the effects of induced pluripotent stem cell (iPSC) treatment on @entity198 and injuries after @entity1779 ( @entity1779 ), though they have shown promising therapeutic potentials in @entity63 stoke. METHODS: An @entity1779 model was established by stereotactic injection of collagenase VII into the left striatum of male Sprague-Dawley (SD) @entity35 . Six hours later, @entity1779 @entity35 were randomly divided into two groups and received intracerebrally 10  l of PBS with or without 1*106 of iPSCs. Subsequently, neural function of all @entity1779 @entity35 was assessed at days 1, 3, 7, 14, 28 and 42 after @entity1779 . Inflammatory cells, cytokines and neural apoptosis in the @entity35 ' perihematomal regions, and brain water content were determined on day 2 or 3 post @entity1779 . iPSC differentiation was determined on day 28 post @entity1779 . Nissl+ cells and @entity40 ( @entity40 )+ cells in the perihematoma and the survival rates of @entity35 in two groups were determined on post- @entity1779 day 42. RESULTS: Compared with control animals, iPSCs treatment not only improved neurological function and survival rate, but also resulted in fewer intracephalic infiltrations of neutrophils and microglia, along with decreased @entity3426 , @entity568 and @entity5 necrosis factor-alpha ( @entity1505 ), and increased @entity13358 in the perihematomal tissues of @entity1779 @entity35 . Furthermore, brain @entity4 formation, apoptosis, injured neurons and @entity66 formation were decreased in iPSCs-transplanted @entity35 . CONCLUSIONS: Our findings indicate that iPSCs transplantation attenuate cerebral inflammatory reactions and @entity130 after @entity1779 , and suggests that multiple mechanisms including inflammation modulation, neuroprotection and functional recovery might be involved simultaneously in the therapeutic benefit of iPSC treatment against @entity64 .

Transplantation of Induced Pluripotent Stem Cells Alleviates @entity198 and Neural Damage in XXXX .

@entity64 :: ('MESH:D020521', 'Disease') :: ['hemorrhagic stroke'] @entity198 :: ('MESH:D004660', 'Disease') :: ['acute cerebral inflammation'] @entity66 :: ('MESH:D004194', 'Disease') :: ['glial scar'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity13358 :: ('25325(Tax:10116)', 'Gene') :: ['IL-10'] @entity568 :: ('24498(Tax:10116)', 'Gene') :: ['IL-6'] @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema'] @entity1505 :: ('24835(Tax:10116)', 'Gene') :: ['TNF-a'] @entity40 :: ('24387(Tax:10116)', 'Gene') :: ['GFAP', 'glial fibrillary acidic protein'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['interleukin (IL)-1b'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['ICH', 'intracerebral hemorrhage'] @entity130 :: ('MESH:D014947', 'Disease') :: ['neural injuries']
@entity64 :: (MESH:D020521,Disease) :: ['Hemorrhagic Stroke']
